PET Study With 11 C-PIB to Evaluate Amyloid Protein Deposits in Mild Cognitive Disorder, Alzheimer's Disease and Early Frontotemporal Degeneration.
NCT06179979 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2023-12-22
Summary
Preclinical and clinical data have demonstrated the ability of the 11C-PIB tracer to selectively bind accumulations of amyloid protein, a neuropathological marker characteristic of the neurodegenerative pathologies covered by this study.
The validation in larger groups of patients, and the comparison between the different clinical syndromes included in the spectrum, will allow the diagnostic and prognostic potential of the tracer to be evaluated, with important consequences for the clinical management of patients.
In particular, the tracer could play a central role in the clinical management of patients with neurodegenerative diseases and cognitive impairment.
Numerous pharmacological trials are currently underway, worldwide, for the validation of anti-amyloid drugs. In the future we could think about early monitoring with imaging of the effectiveness of the treatment.
T he FDG PET technique can be of great help in obtaining relationships between radiation damage to the brain and possibly neurological and neuropsychological deficits associates.
Conditions
- Alzheimer Disease
Interventions
- DIAGNOSTIC_TEST
-
PET/CT with 11C-PiB
Subjects considered suitable will undergo a clinical and neuropsychological evaluation and a PET/CT study with intravenous administration of 11C-PIB.
Sponsors & Collaborators
-
IRCCS San Raffaele
lead OTHER
Eligibility
- Min Age
- 40 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-05-17
- Primary Completion
- 2008-07-15
- Completion
- 2008-07-15
More Related Trials
-
Impact of Microglial Activation on Synaptic Density in Alzheimer's Disease
NCT05911178 ·Status: RECRUITING ·Phase: NA
-
FluoroAv45 Imaging Research-in Alzheimer's Disease
NCT01325259 ·Status: COMPLETED ·Phase: PHASE2
-
Imaging of Brain Amyloid Plaques in the Aging Population
NCT00950430 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4
-
Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD
NCT02681172 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants
NCT02187627 ·Status: COMPLETED ·Phase: PHASE1
-
11C-PIB PET Study in MESA at Columbia University
NCT03981380 ·Status: COMPLETED
-
Influence of Age on Amyloid Load in Alzheimer's Disease and in Atypical Focal Cortical Alzheimer's Disease
NCT01095744 ·Status: COMPLETED
-
Amyloid PET in Patients With Mild Cognitive Impairment and Early Dementia
NCT06402370 ·Status: RECRUITING
-
Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid
NCT00692705 ·Status: COMPLETED ·Phase: PHASE1
-
UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy
NCT03503331 ·Status: RECRUITING ·Phase: PHASE2
-
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
NCT05456503 ·Status: RECRUITING ·Phase: PHASE3
-
Imaging Tau Deposition in the Brain of Elderly Subjects
NCT02958670 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Study of the Indications for Amyloid Positon Emission Tomography (PET) Scans and Their Usefulness for Patients With Suspected Alzheimer's Disease (AD)
NCT06467981 ·Status: COMPLETED
-
Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558
NCT01217021 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Modelling in the Quantitative Analysis of Brain PET Scans in Patients With Alzheimer's Disease
NCT04718207 ·Status: COMPLETED
-
Early Diagnosis of Alzheimer-like Dementia: Benefit of MRI and PET Imaging
NCT01815112 ·Status: TERMINATED ·Phase: NA
-
PET Study of Acetylcholine Esterase Activity in Alzheimer's Disease
NCT06180252 ·Status: COMPLETED
-
Aβ PET and Tau PET Imaging in the Diagnosis and Progression Assessment of Alzheimer's Disease
NCT07114224 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Imaging Tau in Alzheimer's Disease and Normal Aging
NCT03373604 ·Status: COMPLETED ·Phase: PHASE2
-
Incremental Diagnostic Value of Tau-PET With [18F]RO948 vs Amyloid-PET in Patients With Cognitive Impairment
NCT06618872 ·Status: RECRUITING ·Phase: NA
-
18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls
NCT03625128 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases
NCT05260151 ·Status: UNKNOWN
-
PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO)
NCT02062099 ·Status: COMPLETED ·Phase: PHASE1
-
Imaging Inflammation in Alzheimer's Disease
NCT02831283 ·Status: COMPLETED ·Phase: PHASE2
-
Characterization of Cerebral Tau Aggregates With 18F-RO6958948 PET in the ALFA Population
NCT04482660 ·Status: ENROLLING_BY_INVITATION ·Phase: NA